GEO Investing

This week, we hosted a Management Morning Briefing Skull Session with Bryan McLaren, CEO of Zoned Properties Inc (OOTC:ZDPY), a company currently included in our Run to One (R21) Model Portfolio. This portfolio is specifically curated to identify stocks trading below $1.00 that could have the potential to increase to a price of well over $1.00 if business objectives are met.

McLaren highlighted Zoned Properties’ operating history, management team, and capital allocation strategy, emphasizing their current focus on reaching profitability and driving margin growth.

We created the following clips from our conversation with Bryan:

Bryan’s goal is to meet GeoInvesting’s quality standards of a Tier One Microcap;
The inflection point as a result of deploying smart capital into creative acquisition projects;
ZDPY’s Zonomics relationship for mapping out potential grow and dispensary locations;
What does ZDPY have to do to get to profitability?;
Expansion to non-cannabis verticals.

This week, we hosted a Management Morning Briefing Skull Session with Bryan McLaren, CEO of Zoned Properties Inc (OOTC:ZDPY), a company currently included in our Run to One (R21) Model Portfolio. This portfolio is specifically curated to identify stocks trading below $1.00 that could have the potential to increase to a price of well over $1.00 if business objectives are met.

McLaren highlighted Zoned Properties’ operating history, management team, and capital allocation strategy, emphasizing their current focus on reaching profitability and driving margin growth.

We created the following clips from our conversation with Bryan:

Bryan’s goal is to meet GeoInvesting’s quality standards of a Tier One Microcap;
The inflection point as a result of deploying smart capital into creative acquisition projects;
ZDPY’s Zonomics relationship for mapping out potential grow and dispensary locations;
What does ZDPY have to do to get to profitability?;
Expansion to non-cannabis verticals.

It’s ironic that company filings, earnings conference call transcripts, social media, letters to shareholders, data sources, and the internet have made it easier for investors to find InfoArb and use it to their advantage, but so many fail to do so. Why? Besides possibly not having a time to go through all these sources of information, now that more information is available than ever, it’s everywhere, so where do you start?

We find the conference call transcripts to be particularly valuable resources. It’s exciting to know that when companies report their quarterly earnings, the “accomplice” to great findings might be that not-so-well-attended live conference call. The call’s transcript will then reside on platforms like Seeking Alpha and Sentieo, which we happen to subscribe to.

Maj has a quick discussion with $CCEL CEO David Portnoy about current events going on at the company. CCEL provides private and public cord blood banking solutions for stem cell treatments. Specifically, David addressed questions on Revenue trends, Birth rate cause and effect on the company, Pricing environment, Expenditures and run rates, The company’s clinic plans, The shift in revenue expectations, FDA approval goals, Therapy pipeline